SHANGHAI and HONG KONG, March 17, 2026 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that it will present results from three preclinical studies in poster presentations at the 2026 American Association fo

Initial Phase 1 data from Verismo's STAR-101 clinical trial assessing SynKIR™-110 in mesothelin-expressing solid tumors to be released in oral late-breaking presentation; preclinical and initial Phase 1 data from CELESTIAL-301 assessing SynKIR™-310 in B cell Non-Hodgkin Lymphoma to be released in separate poster presentation SynKIR™-110 and SynKIR™-310 are the first multi-chain KIR-CAR-based immuno-oncology therapies in human trials Verismo's multi-chain KIR-CAR technology – inspired by natura

TAIPEI and SAN DIEGO, March 17, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its first-in-class investigational drug Pidnarulex (CX-5461) has demonstrated a significant research breakthrough in the field of photodynamic therapy (PDT). The research findings have been selected for presentation at the 2026 Annual Meeting of the Ame

CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new data for zidesamtinib, an investigational ROS1-selective inhibitor, during two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026, being held April 17-22 in San Diego. The posters will highlight

NEWTON, Mass., March 17, 2026 /PRNewswire/ -- GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, today announced that it has been selected to deliver a late-breaking oral presentation highlighting translational data of GV20-0251 at the American Association of Cancer Research 2026 Annual Meeting, taking place in San Diego on April 17- 22, 2026. This presentation at AACR builds on previously presented clinical data of the novel immune checkpoint IGSF8 inhibitor GV20-025

Clinical data demonstrate IBTROZI's unprecedented durability in TKI-naïve advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) now increased to 50 months as of August 2025 data cutoff Presentations will also highlight new data on the efficacy and safety of taletrectinib in TKI-pretreated patients with ROS1+ NSCLC NEW YORK, March 17, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the

WALTHAM, Mass., March 17, 2026 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, antibody-based therapeutics for patients with autoimmune diseases and cancer, today announced it will present clinical data from its Phase 1/2a trial of first-in-class anti-CD161 antibody, IMT-009, at the American Association for Cancer Research (AACR) Annual Meeting, held April 17-22, 2026 in San Diego, California. D

Innovative Investigational Ventricular Assist Device Marks Major Step Forward in Patient Care BURLINGTON, Mass., March 17, 2026 /PRNewswire/ -- BrioHealth Solutions () today announces the successful implantation of its 100th BrioVAD System, an investigational Ventricular Assist Device (VAD) designed to support patients with advanced heart failure. For INNOVATE Trial Study Details, visit . Continue Reading INNOVATE Trial Logo (PRNewsfoto/BrioHealth Solutions, Inc.) At the forefront of mechanical

Clinical trial will examine whether early plasma resuscitation can improve outcomes for patients with life-threatening burn injuries PHOENIX, March 17, 2026 /PRNewswire/ -- The Diane and Bruce Halle Arizona Burn Center at Valleywise Health is conducting a research study that will look at whether plasma, early in the course of treatment would help severely burned patients survive their injuries. Continue Reading Diane and Bruce Halle Arizona Burn Center at Valleywise Health The Plasma Resuscitati

Minute-by-Minute Measurement of Furosemide Urine Response Predicts 30-Day Mortality in ICU Patients within 15 minutes NEW YORK, March 17, 2026 /PRNewswire/ -- FIZE Medical is pleased to share that a clinical research abstract featuring data obtained using the FIZE kUO® platform has been accepted for oral presentation at the world's leading critical care conference, Critical Care Congress (SCCM), taking place March 22-24, 2026. The data will be presented by Dr. Ohad Gabbay, a senior attending ph